Systemic Treatment of Cutaneous Lymphomas

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Standard

Systemic Treatment of Cutaneous Lymphomas. / Kamstrup, Maria R.; Specht, Lena.

Non-melanoma Skin Cancer: Essentials for Oncologists. red. / Agata Rembielak; Luca Tagliaferri. CRC Press, 2023. s. 355-364.

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Harvard

Kamstrup, MR & Specht, L 2023, Systemic Treatment of Cutaneous Lymphomas. i A Rembielak & L Tagliaferri (red), Non-melanoma Skin Cancer: Essentials for Oncologists. CRC Press, s. 355-364. https://doi.org/10.1201/9781003226017-25

APA

Kamstrup, M. R., & Specht, L. (2023). Systemic Treatment of Cutaneous Lymphomas. I A. Rembielak, & L. Tagliaferri (red.), Non-melanoma Skin Cancer: Essentials for Oncologists (s. 355-364). CRC Press. https://doi.org/10.1201/9781003226017-25

Vancouver

Kamstrup MR, Specht L. Systemic Treatment of Cutaneous Lymphomas. I Rembielak A, Tagliaferri L, red., Non-melanoma Skin Cancer: Essentials for Oncologists. CRC Press. 2023. s. 355-364 https://doi.org/10.1201/9781003226017-25

Author

Kamstrup, Maria R. ; Specht, Lena. / Systemic Treatment of Cutaneous Lymphomas. Non-melanoma Skin Cancer: Essentials for Oncologists. red. / Agata Rembielak ; Luca Tagliaferri. CRC Press, 2023. s. 355-364

Bibtex

@inbook{459741bef7214391a0621919db8d8ad9,

title = "Systemic Treatment of Cutaneous Lymphomas",

abstract = "Most primary cutaneous lymphomas remain localized in the skin for a long time, and they are treated preferentially with skin-directed therapies. However, a number of systemic treatments is used, either in combination with skin-directed therapies or, when the disease disseminates to other organs, as the sole treatment. Conventional chemotherapy is not very effective in the skin. The treatment of disseminated T-cell lymphomas is rarely curative, and single drugs are generally used. Some systemic treatments are cytostatics, e.g., methotrexate, gemcitabine, and doxorubicine; some are immune modularoty, e.g., retinoids, interferons, and extracorporal photophoresis; and some are new targeted drugs, e.g., histone deacetylase inhibitors, brentuximab vedotin, mogamulizumab, and alemtuzumab. Non-myeloablative allogeneic transplant may be used in patients whose disease cannot be adequately controlled with other measures. Indolent primary cutaneous B-cell lymphomas are treated with rituximab if disseminated. For the aggressive primary cutaneous B-cell lymphomas the primary treatment is rituximab combined with conventional combination chemotherapy. Newer targeted drugs are being investigated.",

author = "Kamstrup, {Maria R.} and Lena Specht",

note = "Publisher Copyright: {\textcopyright} 2023 selection and editorial matter, Agata Rembielak and Luca Tagliaferri; individual chapters, the contributors.",

year = "2023",

doi = "10.1201/9781003226017-25",

language = "English",

isbn = "978-1-032-10371-6",

pages = "355--364",

editor = "Agata Rembielak and Luca Tagliaferri",

booktitle = "Non-melanoma Skin Cancer",

publisher = "CRC Press",

}

RIS

TY - CHAP

T1 - Systemic Treatment of Cutaneous Lymphomas

AU - Kamstrup, Maria R.

AU - Specht, Lena

PY - 2023

Y1 - 2023

N2 - Most primary cutaneous lymphomas remain localized in the skin for a long time, and they are treated preferentially with skin-directed therapies. However, a number of systemic treatments is used, either in combination with skin-directed therapies or, when the disease disseminates to other organs, as the sole treatment. Conventional chemotherapy is not very effective in the skin. The treatment of disseminated T-cell lymphomas is rarely curative, and single drugs are generally used. Some systemic treatments are cytostatics, e.g., methotrexate, gemcitabine, and doxorubicine; some are immune modularoty, e.g., retinoids, interferons, and extracorporal photophoresis; and some are new targeted drugs, e.g., histone deacetylase inhibitors, brentuximab vedotin, mogamulizumab, and alemtuzumab. Non-myeloablative allogeneic transplant may be used in patients whose disease cannot be adequately controlled with other measures. Indolent primary cutaneous B-cell lymphomas are treated with rituximab if disseminated. For the aggressive primary cutaneous B-cell lymphomas the primary treatment is rituximab combined with conventional combination chemotherapy. Newer targeted drugs are being investigated.

AB - Most primary cutaneous lymphomas remain localized in the skin for a long time, and they are treated preferentially with skin-directed therapies. However, a number of systemic treatments is used, either in combination with skin-directed therapies or, when the disease disseminates to other organs, as the sole treatment. Conventional chemotherapy is not very effective in the skin. The treatment of disseminated T-cell lymphomas is rarely curative, and single drugs are generally used. Some systemic treatments are cytostatics, e.g., methotrexate, gemcitabine, and doxorubicine; some are immune modularoty, e.g., retinoids, interferons, and extracorporal photophoresis; and some are new targeted drugs, e.g., histone deacetylase inhibitors, brentuximab vedotin, mogamulizumab, and alemtuzumab. Non-myeloablative allogeneic transplant may be used in patients whose disease cannot be adequately controlled with other measures. Indolent primary cutaneous B-cell lymphomas are treated with rituximab if disseminated. For the aggressive primary cutaneous B-cell lymphomas the primary treatment is rituximab combined with conventional combination chemotherapy. Newer targeted drugs are being investigated.

U2 - 10.1201/9781003226017-25

DO - 10.1201/9781003226017-25

M3 - Book chapter

AN - SCOPUS:85149569898

SN - 978-1-032-10371-6

SN - 978-1- 032-12741-5

SP - 355

EP - 364

BT - Non-melanoma Skin Cancer

A2 - Rembielak, Agata

A2 - Tagliaferri, Luca

PB - CRC Press

ER -

ID: 367087365